ONCOlog enters into an agreement with IBA of Belgium

LinkMed’s portfolio company ONCOlog Medical has entered into a partnership agreement with IBA of Belgium. Under the terms of the agreement ONCOlog Medical will provide patient logistics systems to IBA’s proton therapy clinics. IBA holds 50 percent of the world market for proton and particle therapy clinics.

“This marks the start of a period of strong growth for ONCOlog Medical. The partnership gives us a strong position in the proton therapy market, a market that is expected to grow robustly in the next 10-15 years. As a result of the agreement, I expect that we will need to reinforce our operations with 20-25 employees over the next three years,” says Hans Dahlin, CEO, ONCOlog Medical.

ONCOlog Medical shall develop their patient logistics system, PatLog, for use in IBA’s proton therapy clinics. ONCOlog Medical holds several important patents for PatLog. The order value for each PatLog system is estimated at SEK 10-15 million, plus another SEK 10-15 million in after-sales services over a 15-year lifecycle.

Today, there are approximately 20 large proton therapy clinics worldwide, and the technology is advancing rapidly. Over the next few years, 10-15 proton therapy clinics per year are expected to be opened around the world, of which 3-5 per year will be in Europe, where IBA is expected to maintain its strong market position.

LinkMed’s ownership stake in ONCOlog Medical is 48 percent.


For more information contact:
Ingemar Lagerlöf, CEO LinkMed
Tel. +46 8 508 939 93